Research brief / get in touch
Contact Meds Sermorelin
Corrections, sources, and citation questions about the sermorelin digest.
Reach the editorial desk
This is the contact point for the Meds Sermorelin editorial project — the place to send corrections, flag a citation, or suggest a peer-reviewed sermorelin (GHRH(1-29)) study we should read and summarize. We take accuracy seriously: if a figure on the site is wrong or a source is misread, tell us and we will check it against the literature and fix it.
Use the form below to send a message. Please include a link or citation if your note concerns a specific claim.
What we can and can't answer
We can help with editorial matters: which study a number came from, how a finding is framed, or a broken or outdated citation. We cannot provide medical advice, dosing guidance, or personal health recommendations, and we do not sell, source, or supply sermorelin or any other compound. Questions about your own health belong with a qualified clinician, not an editorial digest.
Meds Sermorelin is not a clinic, a pharmacy, or a vendor. It is a sourced reading of published research, and this contact channel exists to keep that reading accurate.
Good corrections to send
The most useful notes point to a specific line and a better source: a study we summarized imprecisely, a figure that should read differently, a citation that has moved or been superseded, or a newer peer-reviewed sermorelin or GHRH-analog paper that changes how a section should read. Because every quantitative claim on this site is tied to a numbered reference, a correction that names the claim and the source is one we can verify and act on quickly. We don't take requests to add promotional language, dosing recommendations, or purchase links — those fall outside what an editorial digest does.
If your note concerns the regulatory framing — sermorelin's approval history is easy to get wrong — a primary regulatory or peer-reviewed citation is especially welcome, since that is the part of the record we most want to keep exact.